ASPEN PHARMACARE HOLDINGS LIMITED - Aspen Secures SAHPRA Approval for Mounjaro as a Chronic Weight Management Treatment

Aspen Secures SAHPRA Approval for Mounjaro® as a Chronic Weight Management Treatment

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively "Aspen" or "the Company" or "the Group")


ASPEN SECURES SAHPRA APPROVAL FOR MOUNJARO® AS A CHRONIC WEIGHT MANAGEMENT TREATMENT

Aspen is pleased to announce the South African Health Products Regulatory Authority ("SAHPRA") has
approved a new indication for the once-weekly prescription only treatment, Mounjaro®(tirzepatide),
as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management,
effective October 2025(i).

Aspen launched Lilly's Mounjaro® (tirzepatide), the first dual glucose-dependent insulinotropic
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, in December 2024 for the
treatment of Type 2 diabetes in South Africa.

Obesity is a chronic and progressive disease that currently impacts more than 1 billion people
worldwide, with a projection of more than half the global population living with obesity and
overweight by 2035(ii),(iii),(iv).

South African patients and healthcare professionals can now look forward to accessing Mounjaro®
(tirzepatide) in an innovative and convenient KwikPen®, which is a multidose injector device, allowing
for an easy delivery system of four fixed doses(v).

Mounjaro® (tirzepatide) KwikPen-pre-filled injection is launched for South African patients, marking a
new level of ease and accessibility for patients requiring regular administration of Mounjaro®
(tirzepatide) for both Type 2 diabetes and weight loss management indications, as advised by
healthcare professionals.

Durban
13 October 2025

Sponsor
Investec Bank Limited




(i) Mounjaro® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management.
Mounjaro® SAHPRA approved Professional Information (10/2025)
(ii) World Health Organization. World Obesity Day 2022 – Accelerating action to stop obesity. Updated March 4, 2022. Accessed
February 20, 2024. https://www.who.int/news/item/04-03-2022-world-obesity-day-2022-accelerating-action-to-stop-obesity
(iii) World Obesity Atlas 2023. March 2023. Accessed February 20, 2024. https://s3-eu-west1.amazonaws.com/wof-
files/World_Obesity_Atlas_2023_Report.pdf
(iv) World Obesity Atlas 2024. March 2023. Accessed March 6, 2024. https://data.worldobesity.org/publications/WOF-Obesity-
Atlas-v6.pdf
(v) Mounjaro KwikPen SAHPRA approved Professional Information (07/2025)

Date: 13-10-2025 10:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.